Adial pharmaceuticals announces $4 million private placement priced at-the-market under nasdaq rules

Charlottesville, va., oct. 20, 2023 (globe newswire) -- adial pharmaceuticals, inc. (nasdaq:adil) (“adial” or the “company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,418,440 shares of its common stock (or common stock equivalents in lieu thereof), series a warrants to purchase up to 1,418,440 shares of common stock and series b warrants to purchase up to 1,418,440 shares of common stock, at a purchase price of $2.82 per share of common stock (or common stock equivalent in lieu thereof) and accompanying warrants, in a private placement priced at-the-market under nasdaq rules. the offering is expected to close on or about october 24, 2023, subject to the satisfaction of customary closing conditions.
ADIL Ratings Summary
ADIL Quant Ranking